Related references
Note: Only part of the references are listed.Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin
Yu-Yun Shao et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
George Pentheroudakis et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer
Satoru Tanaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Cristiano Ferlini et al.
CANCER RESEARCH (2009)
Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma
Daisuke Aoki et al.
CLINICAL CANCER RESEARCH (2009)
Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial
Lajos Pusztai et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
Edith A. Perez
MOLECULAR CANCER THERAPEUTICS (2009)
A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship
Britta Stordal et al.
CANCER TREATMENT REVIEWS (2007)
Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
Pascal Seve et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2007)
Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer:: Analysis of NCIC JBR.10
Pascal Seve et al.
CLINICAL CANCER RESEARCH (2007)
Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment
K. Mimori et al.
BRITISH JOURNAL OF CANCER (2006)
Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients
G Ferrandina et al.
CLINICAL CANCER RESEARCH (2006)
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer
R Rouzier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Repeat motifs of tau bind to the insides of microtubules in the absence of taxol
S Kar et al.
EMBO JOURNAL (2003)
Share Paper
